CN106924364A - The purposes of baikal skullcap root and radix paeoniae rubrathe pharmaceutical composition in treatment lung cancer accompanied antidepressant agents are prepared - Google Patents
The purposes of baikal skullcap root and radix paeoniae rubrathe pharmaceutical composition in treatment lung cancer accompanied antidepressant agents are prepared Download PDFInfo
- Publication number
- CN106924364A CN106924364A CN201511029789.4A CN201511029789A CN106924364A CN 106924364 A CN106924364 A CN 106924364A CN 201511029789 A CN201511029789 A CN 201511029789A CN 106924364 A CN106924364 A CN 106924364A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- lung cancer
- radix paeoniae
- paeoniae rubrathe
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the field of Chinese medicines, it is related to baikal skullcap root and the new pharmaceutical usage of radix paeoniae rubrathe pharmaceutical composition, and in particular to the purposes of baikal skullcap root and radix paeoniae rubrathe pharmaceutical composition in treatment lung cancer accompanied antidepressant agents are prepared.The present invention as model, and stress be given pharmaceutical composition and intervened using Mice Bearing Lewis Lung Cancer with social activity, as a result be shown：This pharmaceutical composition can improve mouse in the Social Avoidance behavior of social activity contact spacious field and can effectively suppress the growth of tumour；This pharmaceutical composition is relevant with suppression cortisol and inflammatory factor (TNF-α and IL-6) with depressed improvement result to tumour；This pharmaceutical composition is relevant with suppression tumor tissues nuclear factor-kappa B and VEGF to the inhibitory action of tumour.The root of large-flowered skullcap of the invention and the radix paeoniae rubrathe its pharmaceutical composition can be used to prepare treatment lung cancer accompanied antidepressant agents.
Description
Technical field
The invention belongs to the field of Chinese medicines, it is related to baikal skullcap root and the new pharmaceutical usage of radix paeoniae rubrathe pharmaceutical composition, specifically relates to
And the purposes of baikal skullcap root and radix paeoniae rubrathe pharmaceutical composition in treatment lung cancer accompanied antidepressant agents are prepared.
Background technology：
Data shows according to statistics, and lung cancer is one of morbidity and mortality highest malignant tumour in the world, is accounted for
The depressed incidence of disease of the 12.4% of all tumours, wherein lung cancer accompanied is 16%-44%, hence it is evident that higher than other tumours.
Modern medicine is depressed for lung cancer accompanied still without targetedly treatment means.
In the prior art, having research to disclose Chinese medicine ngre Huoxu e Recipe has antitumor and anti-inflammatory effect, described
Chinese medicine ngre Huoxu e Recipe mainly contains the root of large-flowered skullcap and radix paeoniae rubrathe related component, so far, there is not yet on the root of large-flowered skullcap and the radix paeoniae rubrathe and
Its pharmaceutical composition is to the depressed medicative report of tool of lung cancer accompanied.
In consideration of it, present inventor intend on the basis of zoopery, there is provided Chinese medicine ngre Huoxu e Recipe it is new
Pharmaceutical usage, and in particular to the active principle root of large-flowered skullcap and its pharmaceutical composition of the radix paeoniae rubrathe are in system in Chinese medicine ngre Huoxu e Recipe
Purposes in standby treatment lung cancer accompanied antidepressant agents.
The content of the invention
It is an object of the present invention to provide the new pharmaceutical usage of Chinese medicine ngre Huoxu e Recipe, and in particular to Chinese medicine is clear
The active principle root of large-flowered skullcap and its pharmaceutical composition of the radix paeoniae rubrathe are in treatment lung cancer accompanied antidepressant agents are prepared in hot blood circulation promoting recipe
Purposes.
The root of large-flowered skullcap of the present invention and the radix paeoniae rubrathe its pharmaceutical composition press proportion compatibility 6 by the Chinese medicine root of large-flowered skullcap and the radix paeoniae rubrathe:5
It is made.
Pharmaceutical composition of the present invention has carried out mice lung cancer and has been tested with depression model, and experimental result shows,
The rising of cortisol, TNF-α and IL-6 levels in described pharmaceutical composition energy Inhibition test mouse serum；With
And NF- κ B and vegf protein are expressed in Inhibition test mouse tumor tissues.
In the present invention：Giving the social activity of C57 mouse stress simultaneously be inoculated with Lewis lung carcinoma cells, set up mice lung cancer
With depression model；Using stress method：Aggressive strong CD1 mouse are settler, and C57 mouse are invasion
Person, C57 mouse receive different CD1 mouse challenges daily, continue 3-5 minutes, then put C57 mouse
Enter the mouse cage side being separated by by transparent baffle with holes, it can be seen that and CD1 mouse are smelt, get along 24 hours, even
It is continuous stress ten days；Tumour cell is inoculated with after stress terminating；Period gives pharmaceutical composition of the present invention and carries out
Intervene in vivo, as a result show：This pharmaceutical composition can improve Social Avoidance behavior of the mouse in spacious field, use
Medicine group mouse inhibits the growth of tumour in social distance zone extended residence time；Statistics display：This medicine group
The effect of compound is relevant with the rising for suppressing cortisol, TNF-α and IL-6 levels in serum；This drug regimen
The effect of thing is relevant with NF- κ B in suppression tumor tissues and vegf protein expression.
The root of large-flowered skullcap of the present invention and the radix paeoniae rubrathe its pharmaceutical composition can be used to prepare treatment lung cancer accompanied antidepressant agents.
Brief description of the drawings
Fig. 1：Each group mouse is in the social distance zone residence time when CD1 occurs,
Wherein, compare with normal group, * P<0.05；Compare with model group, #P<0.05.
Fig. 2：Each group mouse hypodermic tumour weight,
Wherein, compare with model group, #P<0.05.
Fig. 3：Serum cortisol, TNF-α, IL-6 expressions,
Wherein, compare with normal group, * P<0.05；Compare with model group, #P<0.05.
Fig. 4：The inhibitory action that this pharmaceutical composition is expressed NF- kB proteins in tumor tissues,
Wherein, A, B, C, D, E are respectively the high, medium and low dosage group of model group, this pharmaceutical composition
Immuning tissue's dyeing of NF- κ B, compares, #P with model group<0.05.
Fig. 5：The inhibitory action that this pharmaceutical composition is expressed vegf protein in tumor tissues,
Wherein, A, B, C, D, E are respectively the high, medium and low dosage group of model group, this pharmaceutical composition
Immuning tissue's dyeing of VEGF, compares, #P with model group<0.05.
Specific embodiment
Embodiment 1：The root of large-flowered skullcap of the present invention and the depressed experiment in vivo of the radix paeoniae rubrathe its pharmaceutical composition improvement lung cancer accompanied
First, materials and methods
1. foundation and packet of the mice lung cancer with depression model
Mice lung cancer is set up with depressed mould using social activity failure Coping style and subcutaneous vaccination Lewis lung carcinoma cells
60 C57 mouse are randomly divided into 6 groups, Normal group by type；Model group；This pharmaceutical composition
High dose group (15g/kg gavages)；This pharmaceutical composition middle dose group (7.5g/kg gavages)；This medicine
Composition low dose group (3.75g/kg gavages)；Double medicine groups (Prozac gavage, Intraperitoneal Cisplatin injection)；
2. mice behavior and tumor weight are detected：
CD1 mouse are the C57 in two 150s not in the case of under usage behavior tracking software records
Movement locus of the mouse in social activity contact spacious field, and be analyzed with behavior analysis software；During materials
The weight of mouse hypodermic tumour is measured with balance；
Cortisol, TNF-α and IL-6 levels in 3.ELISA methods detection mice serum
All mouse orbit arterial blood drawings, after 4 DEG C stand 2h, 3000r/min, 4 DEG C of centrifugation 15min, on
- 80 DEG C of preservations of clear liquid carry out ELISA detections；Illustrated according to kit, cortisol, TNF- in detection serum
α and IL-6 levels；
4. ImmunohistochemistryMethods Methods detect NF- κ B and vegf expression in tumor tissues
By experimental mouse tumor tissues paraffin section it is toasted, be dehydrated, boil, after PBS rinses, through primary antibody,
After secondary antibody is incubated, 100ulDAB 3~5min of colour developing are added dropwise, haematoxylin redyes 30s, hydrochloride alcohol differentiation
1s, after dehydration drying, resin mounting, Microscopic observation, nucleus is in hyacinthine, and positive products are in pale brown
Color or yellow；
2nd, result shows
It is 1. social to contact experimental result,
In the presence of CD1 mouse, model group is than normal group in social distance zone residence time obvious shortening (P<0.05),
Show Social Avoidance behavior；And each dosage group of this pharmaceutical composition compares with model group when social distance zone is stopped
Between extend, difference has conspicuousness (P<0.05), show that this pharmaceutical composition can improve the Social Avoidance of mouse
Behavior, with antidepressant effect；
2. each group mouse hypodermic tumour result
Each dosage group of this pharmaceutical composition equally inhibits the growth of tumour, wherein with high dose group to tumour
Inhibitory action it is the most obvious, three dosage groups and double medicine group comparing differences not significantly (P>0.05)；
3. serum cortisol, TNF-α and IL-6 testing results
Experimental result display model group mouse hpa axis are activated, and cortisol levels are significantly raised in serum, with
Normal group compares (P<0.01)；Compare with model group, each dosage group of this pharmaceutical composition can be reduced in serum
Abnormal elevated cortisol (P<0.05), curative effect no significant difference (P between each dosage group>0.05)；Model group
It is significantly raised compared with inflammatory factor TNF-α in normal group serum and IL-6, show scorching in lung cancer accompanied depression Mice Body
The presence of disease microenvironment, and this pharmaceutical composition can reduce by two kinds of levels of inflammatory factor, compare with model group
Difference has conspicuousness (P<0.05)；With double medicine group comparing differences without conspicuousness (P>0.05)；
4. tumor tissues NF- κ B and vegf expression
This pharmaceutical composition each group and double medicine groups inhibit NF- κ B and vegf protein in mouse hypodermic tumour tissue
Expression, have conspicuousness (P with model group comparing difference<0.01)；Each dosage group of this pharmaceutical composition and double medicines
Group compares, no significant difference (P>0.05).
Claims (5)
1. purposes of the pharmaceutical composition that the root of large-flowered skullcap and the radix paeoniae rubrathe are made in treatment lung cancer accompanied antidepressant agents are prepared.
2. the purposes as described in claim 1, it is characterised in that：In described pharmaceutical composition the root of large-flowered skullcap and the radix paeoniae rubrathe its
Proportion compatibility is 6:5.
3. the purposes as described in claim 1, it is characterised in that：Described pharmaceutical composition suppresses cortex in serum
The rising of alcohol, TNF-α and IL-6 levels.
4. the purposes as described in claim 1, it is characterised in that：Described pharmaceutical composition suppresses in tumor tissues
NF- κ B and vegf protein are expressed.
5. the purposes as described in claim 4, it is characterised in that：Described tumor tissues are cancerous lung tissues.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511029789.4A CN106924364A (en) | 2015-12-31 | 2015-12-31 | The purposes of baikal skullcap root and radix paeoniae rubrathe pharmaceutical composition in treatment lung cancer accompanied antidepressant agents are prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511029789.4A CN106924364A (en) | 2015-12-31 | 2015-12-31 | The purposes of baikal skullcap root and radix paeoniae rubrathe pharmaceutical composition in treatment lung cancer accompanied antidepressant agents are prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106924364A true CN106924364A (en) | 2017-07-07 |
Family
ID=59443695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511029789.4A Pending CN106924364A (en) | 2015-12-31 | 2015-12-31 | The purposes of baikal skullcap root and radix paeoniae rubrathe pharmaceutical composition in treatment lung cancer accompanied antidepressant agents are prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106924364A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114159499A (en) * | 2022-01-12 | 2022-03-11 | 黑龙江中医药大学 | Traditional Chinese medicine composition for treating hepatic fibrosis and preparation method and application thereof |
-
2015
- 2015-12-31 CN CN201511029789.4A patent/CN106924364A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114159499A (en) * | 2022-01-12 | 2022-03-11 | 黑龙江中医药大学 | Traditional Chinese medicine composition for treating hepatic fibrosis and preparation method and application thereof |
| CN114159499B (en) * | 2022-01-12 | 2022-09-06 | 黑龙江中医药大学 | Traditional Chinese medicine composition for treating hepatic fibrosis and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lu et al. | The efficacy and mechanism of Chinese herbal medicine on diabetic kidney disease | |
| Shen et al. | Anti‐ageing active ingredients from herbs and nutraceuticals used in traditional Chinese medicine: pharmacological mechanisms and implications for drug discovery | |
| Zheng et al. | Analysis of the restorative effect of Bu-zhong-yi-qi-tang in the spleen-qi deficiency rat model using 1H-NMR-based metabonomics | |
| Hayasaka et al. | Traditional Japanese herbal (kampo) medicines and treatment of ocular diseases: a review | |
| CN1321679C (en) | Ginger and dried orange peel extracts mixture for treating cardiovascular disease | |
| Ito-Nagahata et al. | Stilbene analogs of resveratrol improve insulin resistance through activation of AMPK | |
| Fan et al. | Atractylenolide I ameliorates cancer cachexia through inhibiting biogenesis of IL‐6 and tumour‐derived extracellular vesicles | |
| Pan et al. | The Effectiveness of Traditional Chinese Medicine Jinlida Granules on Glycemic Variability in Newly Diagnosed Type 2 Diabetes: A Double‐Blinded, Randomized Trial | |
| Ya-Qian et al. | Protective effect of the extract of Yi-Qi-Fu-Mai preparation on hypoxia-induced heart injury in mice | |
| CN106924364A (en) | The purposes of baikal skullcap root and radix paeoniae rubrathe pharmaceutical composition in treatment lung cancer accompanied antidepressant agents are prepared | |
| CN105267867B (en) | Application of traditional Chinese medicine composition in preparation of medicine for eliminating cardiotoxic side effects of adriamycin | |
| Zhang et al. | Qiju Dihuang decoction for hypertension: a systematic review and meta-analysis | |
| CN104784297B (en) | One kind resists allergic composition | |
| CN102204981A (en) | Chinese-medicinal compound lotion for treating dermatitis eczema | |
| CN103623223A (en) | Composition with functions of oxidation resistance and chloasma | |
| Fang et al. | Astilbin protects from sepsis‐induced cardiac injury through the NRF2/HO‐1 and TLR4/NF‐κB pathway | |
| Singh et al. | Enhancement of neuromuscular activity by natural specimens and cultured mycelia of Cordyceps sinensis in mice | |
| CN110433168A (en) | Secoiridoid derivative prevents and treats the application in neurodegenerative disease drug and its pharmaceutical composition of composition in preparation | |
| CN103599449B (en) | Liuwei Anxiao pharmaceutical composition and the application of preparation in preparation treatment alcoholic hepatitis medicine thereof | |
| Wu et al. | Zhibaidihuang Decoction Ameliorates Cell Oxidative Stress by Regulating the Keap1‐Nrf2‐ARE Signalling Pathway | |
| CN110215508A (en) | A kind of preparation process of Shu Yu herbal mixture and its manufactured dosage form and each dosage form | |
| CN104971059A (en) | Application of niclosamide or pharmaceutically acceptable salt thereof in pharmacy | |
| Yan et al. | Validation of the Anticolitis Efficacy of the Jian-Wei-Yu-Yang Formula | |
| CN104491496B (en) | Application of the Gastrodin/Rhizoma Gastrodiae powder in anti-hepatic fibrosis medicines are prepared | |
| CN107753914B (en) | Pharmaceutical composition for treating liver cirrhosis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170707 |
|
| RJ01 | Rejection of invention patent application after publication |